Search

everythinglearnresearchcommunity

for

Search:↓

Frontal fibrosing alopecia is a hair loss condition in postmenopausal women, similar to lichen planopilaris, with ineffective treatments.

Lichen Planus is a less common condition affecting skin and mucous membranes, with various types and associated risk factors, challenging to diagnose, significantly impacts life quality, and may have a risk of cancerous changes in oral lesions.

New insights show Lichen Planopilaris is a rare, scarring hair loss condition, hard to treat, mainly affecting middle-aged women, and significantly impacts mental health.

Lichen planus is a skin condition that can resolve on its own, is linked to hepatitis C, and increases the risk of skin cancer.

The conclusion is that FFA and LPP have similar scalp biopsy features, making them hard to distinguish histologically, and FFA may be a specific kind of scarring hair loss.

No effective treatment for frontal fibrosing alopecia was found, but oral 5-alpha-reductase inhibitors had the best response; for lichen planopilaris, topical corticosteroids were commonly used but had a high relapse rate.

The study found that steroids and tetracycline helped treat active Lichen planopilaris, and hair transplants were good for later stages.

A specific drug can help treat Lichen Planopilaris, a condition causing permanent hair loss.

Lichen planus pigmentosus causes dark skin patches and is treated by avoiding triggers and using anti-inflammatory medications.

Lichen planopilaris is a chronic, scarring hair loss condition with no definitive cure, requiring accurate diagnosis and treatment to manage symptoms.

A premenopausal woman had hair loss and skin issues, treated with topical steroids.

There may be a connection between Frontal Fibrosing Alopecia and Lichen Planus Pigmentosus, and more research is needed to confirm this.

Lichen Planopilaris and Frontal Fibrosing Alopecia may help us understand hair follicle stem cell disorders and suggest new treatments.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

The conclusion is that certain scalp tissue changes are characteristic of lichen planopilaris, with mucinous perifollicular fibroplasia being a new feature for diagnosis.

Mycophenolate mofetil was effective for most patients in treating scarring hair loss, but some had side effects.

Alefacept may effectively treat severe lichen planus, with patients showing significant improvement and no side effects.

Women are more likely to have Lichen planopilaris, and treatments with cyclosporine and methotrexate are most effective but less safe than mycophenolate mofetil.

Most treatments for lichen planopilaris were found to be generally unsatisfactory.

People with lichen planus have higher bad cholesterol and lower good cholesterol, increasing their risk for heart disease.

Lichen planopilaris (LPP) is linked to androgen excess, while frontal fibrosing alopecia (FFA) is linked to androgen deficiency.

No treatment showed clear superiority for lichen planopilaris.

Etretinate has only moderate effects on localized scleroderma and lichen sclerosus.

Low-dose naltrexone helps reduce symptoms and slow down lichen planopilaris without side effects.

Etanercept may cause lichen planopilaris, so doctors should be cautious.

Lichen planopilaris mostly affects women with fair skin and can look different on each person, needing early treatment to prevent hair loss.

Thalidomide significantly improved hair regrowth in a woman with lichen planopilaris.

Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.

Lichen planus is linked to several autoimmune diseases.